PRA Health Sciences, Inc. is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases. Its services include data management, statistical analysis, clinical trial management, and regulatory and drug development consulting. It provides its clients with clinical development service offerings, which includes both traditional, project-based Phase I through Phase IV services, as well as embedded and functional outsourcing services. As of December 31, 2016, its clinical development platform included approximately 70 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East. The Company's service offerings include product registration, strategic solutions and early development services.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:PRAH
- CUSIP: N/A
- Web: www.prahs.com
Capitalization:- Market Cap: $4.7 billion
- Outstanding Shares: 62,651,000
Average Prices:- 50 Day Moving Avg: $75.71
- 200 Day Moving Avg: $70.59
- 52 Week Range: $50.87 - $80.99
P/E:- Trailing P/E Ratio: 48.47
- Foreward P/E Ratio: 19.50
- P/E Growth: 1.25
Sales & Book Value:- Annual Revenue: $1.7 billion
- Price / Sales: 2.77
- Book Value: $13.45 per share
- Price / Book: 5.58
Profitability:- EBIDTA: $250.95 million
- Net Margins: 5.15%
- Return on Equity: 21.17%
- Return on Assets: 7.23%
Debt:- Debt-to-Equity Ratio: 0.94%
- Current Ratio: 1.17%
- Quick Ratio: 1.17%
Misc:- Average Volume: 642,870 shs.
- Beta: 0.45
- Short Ratio: 2.78
Frequently Asked Questions for PRA Health Sciences (NASDAQ:PRAH)
What is PRA Health Sciences' stock symbol?
PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."
How were PRA Health Sciences' earnings last quarter?
PRA Health Sciences, Inc. (NASDAQ:PRAH) released its earnings results on Monday, August, 7th. The company reported $0.62 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.72 by $0.10. The business had revenue of $457.90 million for the quarter, compared to analyst estimates of $447.79 million. PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. PRA Health Sciences's quarterly revenue was up .5% compared to the same quarter last year. During the same quarter last year, the company earned $0.63 earnings per share. View PRA Health Sciences' Earnings History.
When will PRA Health Sciences make its next earnings announcement?
What guidance has PRA Health Sciences issued on next quarter's earnings?
PRA Health Sciences issued an update on its FY17 earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of $3.11-$3.20 for the period, compared to the Thomson Reuters consensus estimate of $3.15. The company issued revenue guidance of $1.825-$1.855 billion, compared to the consensus revenue estimate of $1.82 billion.
Where is PRA Health Sciences' stock going? Where will PRA Health Sciences' stock price be in 2017?
10 brokers have issued twelve-month price targets for PRA Health Sciences' shares. Their predictions range from $63.00 to $93.00. On average, they expect PRA Health Sciences' share price to reach $84.38 in the next year. View Analyst Ratings for PRA Health Sciences.
Who are some of PRA Health Sciences' key competitors?
Some companies that are related to PRA Health Sciences include Alkermes PLC (ALKS), Seattle Genetics (SGEN), Qiagen N.V. (QGEN), Ionis Pharmaceuticals (IONS), Icon Plc (ICLR), Exact Sciences Corporation (EXAS), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), Puma Biotechnology (PBYI), FibroGen (FGEN), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA), Ligand Pharmaceuticals Incorporated (LGND) and INC Research Holdings (INCR).
Who are PRA Health Sciences' key executives?
PRA Health Sciences' management team includes the folowing people:
- Colin Shannon, Chairman of the Board, President, Chief Executive Officer
- Linda Baddour, Chief Financial Officer, Executive Vice President
- David W. Dockhorn Ph.D., Executive Vice President, Corporate Compliance Officer
- Max C. Lin, Director
- James C. Momtazee, Director
- Ali J. Satvat, Director
- Jeffrey T. Barber, Independent Director
- Alexander George Dickinson Ph.D., Independent Director
When did PRA Health Sciences IPO?
(PRAH) raised $306 million in an initial public offering (IPO) on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.
Who owns PRA Health Sciences stock?
PRA Health Sciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.29%), BlackRock Inc. (5.86%), Capital Research Global Investors (3.47%), Acadian Asset Management LLC (3.13%), Eagle Asset Management Inc. (1.80%) and Bamco Inc. NY (1.52%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.
Who sold PRA Health Sciences stock? Who is selling PRA Health Sciences stock?
PRA Health Sciences' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., FMR LLC, Acadian Asset Management LLC, Principal Financial Group Inc., Prudential Financial Inc., TimesSquare Capital Management LLC, Numeric Investors LLC and Canada Pension Plan Investment Board. Company insiders that have sold PRA Health Sciences stock in the last year include Colin Shannon, David W Dockhorn, Linda Baddour and Pra Investors LP Kkr. View Insider Buying and Selling for PRA Health Sciences.
Who bought PRA Health Sciences stock? Who is buying PRA Health Sciences stock?
PRA Health Sciences' stock was acquired by a variety of institutional investors in the last quarter, including Capital Research Global Investors, BlackRock Inc., Harbour Capital Advisors LLC, Hood River Capital Management LLC, State Street Corp, Russell Investments Group Ltd., South Texas Money Management Ltd. and Wells Fargo & Company MN. View Insider Buying and Selling for PRA Health Sciences.
How do I buy PRA Health Sciences stock?
Shares of PRA Health Sciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PRA Health Sciences' stock price today?
One share of PRA Health Sciences stock can currently be purchased for approximately $75.09.
MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for PRA Health Sciences (NASDAQ:PRAH) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 9 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.90) |
| Consensus Price Target: | $84.38 (12.37% upside) |
Analysts' Ratings History for PRA Health Sciences (NASDAQ:PRAH)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/21/2017 | Mizuho | Initiated Coverage | Buy | $82.00 | Low |  |
| 8/16/2017 | Raymond James Financial, Inc. | Initiated Coverage | Outperform -> Outperform | $89.00 | Low | |
| 8/10/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $88.00 -> $92.00 | Low | |
| 8/10/2017 | Citigroup Inc. | Reiterated Rating | Buy | $90.00 -> $93.00 | Low | |
| 8/9/2017 | SunTrust Banks, Inc. | Reiterated Rating | Buy | | High | |
| 8/8/2017 | Credit Suisse Group | Boost Price Target | Outperform -> Outperform | $80.00 -> $84.00 | High | |
| 8/8/2017 | Robert W. Baird | Boost Price Target | Outperform | $82.00 -> $83.00 | High | |
| 6/26/2017 | Bank of America Corporation | Initiated Coverage | Buy | $89.00 | Low | |
| 2/27/2017 | Avondale Partners | Upgrade | Underperform -> Market Perform | $63.00 | N/A | |
| 11/4/2016 | KeyCorp | Reiterated Rating | Buy | | N/A | |
| 6/20/2016 | First Analysis | Initiated Coverage | Equal -> Equal Weight | $47.00 | N/A | |
(Data available from 9/22/2015 forward)
Earnings History for PRA Health Sciences (NASDAQ:PRAH)Earnings History by Quarter for PRA Health Sciences (NASDAQ PRAH)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | $0.85 | | | | | N/A | |
| 8/7/2017 | Q2 2017 | $0.72 | $0.62 | $447.79 million | $457.90 million | View | Listen | |
| 4/25/2017 | Q1 2017 | $0.58 | $0.60 | $426.81 million | $427.08 million | View | N/A | |
| 2/22/2017 | Q4 2016 | $0.64 | $0.71 | $405.04 million | $413.61 million | View | N/A | |
| 11/2/2016 | Q316 | $0.64 | $0.64 | $394.87 million | $399.80 million | View | N/A | |
| 7/28/2016 | Q2 | $0.59 | $0.63 | $381.25 million | $394.20 million | View | Listen | |
| 4/27/2016 | Q116 | $0.53 | $0.55 | $372.21 million | $372.30 million | View | Listen | |
| 2/24/2016 | Q4 | $0.49 | $0.59 | $353.42 million | $428.90 million | View | Listen | |
| 11/2/2015 | Q3 | $0.45 | $0.52 | $346.05 million | $345.10 million | View | Listen | |
| 7/27/2015 | Q215 | $0.40 | $0.47 | $336.74 million | $336.50 million | View | Listen | |
| 5/6/2015 | Q115 | $0.31 | $0.41 | $329.80 million | $332.00 million | View | Listen | |
| 2/18/2015 | Q414 | $0.30 | $0.35 | $323.50 million | $370.00 million | View | Listen | |
(Data available from 1/1/2011 forward)
Earnings Estimates for PRA Health Sciences (NASDAQ:PRAH)2017 EPS Consensus Estimate: $3.05
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.57 | $0.66 | $0.62 |
| Q2 2017 | 3 | $0.68 | $0.79 | $0.73 |
| Q3 2017 | 4 | $0.80 | $0.83 | $0.82 |
| Q4 2017 | 4 | $0.85 | $0.92 | $0.89 |
| Q2 2018 | 1 | $0.92 | $0.92 | $0.92 |
(Data provided by Zacks Investment Research)
Dividend History for PRA Health Sciences (NASDAQ:PRAH)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for PRA Health Sciences (NASDAQ:PRAH)Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 98.37%
Insider Trades by Quarter for PRA Health Sciences (NASDAQ:PRAH)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/14/2017 | Colin Shannon | CEO | Sell | 400,000 | $74.85 | $29,940,000.00 | |
| 8/14/2017 | Linda Baddour | VP | Sell | 100,000 | $74.85 | $7,485,000.00 | |
| 8/14/2017 | Pra Investors L.P. Kkr | Major Shareholder | Sell | 9,500,000 | $74.85 | $711,075,000.00 | |
| 4/17/2017 | Linda Baddour | VP | Sell | 196,393 | $63.59 | $12,488,630.87 | |
| 3/28/2017 | Colin Shannon | CEO | Sell | 50,000 | $64.00 | $3,200,000.00 | |
| 3/27/2017 | David W Dockhorn | Insider | Sell | 85,182 | $62.00 | $5,281,284.00 | |
| 2/23/2017 | Colin Shannon | CEO | Sell | 100,000 | $61.50 | $6,150,000.00 | |
| 8/22/2016 | Colin Shannon | CEO | Sell | 113,133 | $51.57 | $5,834,268.81 | |
| 8/15/2016 | Linda Baddour | VP | Sell | 69,380 | $52.00 | $3,607,760.00 | |
| 8/12/2016 | David W. Dockhorn | VP | Sell | 107,257 | $49.00 | $5,255,593.00 | |
| 5/6/2016 | Linda Baddour | CFO | Sell | 92,308 | $46.70 | $4,310,783.60 | |
| 5/6/2016 | Pra Investors L.P. Kkr | Major Shareholder | Sell | 4,907,692 | $46.70 | $229,189,216.40 | |
| 3/8/2016 | Colin Shannon | CEO | Sell | 77,019 | $42.26 | $3,254,822.94 | |
| 3/8/2016 | Linda Baddour | CFO | Sell | 93,000 | $42.26 | $3,930,180.00 | |
| 3/8/2016 | Pra Investors L.P. Kkr | Major Shareholder | Sell | 4,829,981 | $42.26 | $204,114,997.06 | |
(Data available from 1/1/2013 forward)
Headline Trends for PRA Health Sciences (NASDAQ:PRAH)
Latest Headlines for PRA Health Sciences (NASDAQ:PRAH)
| Source: |
|
| Date | Headline |
|---|
 | PRA Health Sciences, Inc. (PRAH) Receives New Coverage from Analysts at Mizuho
www.americanbankingnews.com - September 21 at 10:02 AM |
 | PRA Health Sciences, Inc. breached its 50 day moving average in a Bearish Manner : PRAH-US : September 14, 2017
finance.yahoo.com - September 15 at 7:46 AM |
| PRA Health Sciences, Inc. (PRAH) Downgraded by Zacks Investment Research
www.americanbankingnews.com - September 15 at 6:14 AM |
| PRA Health Sciences, Inc. (PRAH) Expected to Post Quarterly Sales of $470.60 Million
www.americanbankingnews.com - September 14 at 8:48 AM |
| PRA closes $530M acquisition
finance.yahoo.com - September 13 at 7:58 AM |
| PRA Health Sciences, Inc. (PRAH) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - September 9 at 8:52 PM |
| A list of executives that have sold $3M-plus in stock of Triangle companies
finance.yahoo.com - September 9 at 7:31 AM |
| PRA Health Sciences, Inc. (PRAH) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - September 7 at 6:34 AM |
| PRA Health Sciences, Inc. (PRAH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - August 30 at 11:50 PM |
| PRA Health Sciences, Inc. (PRAH) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 30 at 2:34 PM |
| Zacks Investment Research Downgrades PRA Health Sciences, Inc. (PRAH) to Hold
www.americanbankingnews.com - August 29 at 8:40 AM |
| PRA Health Sciences, Inc. breached its 50 day moving average in a Bearish Manner : PRAH-US : August 21, 2017
finance.yahoo.com - August 22 at 5:48 AM |
| Zacks Investment Research Lowers PRA Health Sciences, Inc. (PRAH) to Hold
www.americanbankingnews.com - August 21 at 6:06 AM |
| PRA Health Sciences, Inc. to Post Q4 2017 Earnings of $0.85 Per Share, KeyCorp Forecasts (PRAH)
www.americanbankingnews.com - August 18 at 9:40 AM |
 | Pra Health Sciences Inc (PRAH) President & CEO Colin Shannon Sold $29.9 million of Shares
www.nasdaq.com - August 18 at 1:22 AM |
| Earnings Review and Free Research Report: DexCom’s Q2 Top-line Surged 24%; Outshined Forecasts
finance.yahoo.com - August 17 at 3:19 PM |
| First Analysis Weighs in on PRA Health Sciences, Inc.'s Q2 2018 Earnings (PRAH)
www.americanbankingnews.com - August 17 at 12:54 PM |
| PRA Health Sciences, Inc. (PRAH) Research Coverage Started at Raymond James Financial, Inc.
www.americanbankingnews.com - August 16 at 8:58 PM |
| Pra Investors L.P. Kkr Sells 9,500,000 Shares of PRA Health Sciences, Inc. (PRAH) Stock
www.americanbankingnews.com - August 16 at 7:39 PM |
| Colin Shannon Sells 400,000 Shares of PRA Health Sciences, Inc. (PRAH) Stock
www.americanbankingnews.com - August 16 at 4:54 PM |
| PRA Health Sciences, Inc. (PRAH) VP Sells $7,485,000.00 in Stock
www.americanbankingnews.com - August 16 at 4:54 PM |
| See what the IHS Markit Score report has to say about PRA Health Sciences Inc.
finance.yahoo.com - August 16 at 6:55 AM |
| PRA Health Sciences, Inc. (PRAH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 15 at 6:40 PM |
| Research Analysts Offer Predictions for PRA Health Sciences, Inc.'s FY2017 Earnings (NASDAQ:PRAH)
www.americanbankingnews.com - August 14 at 5:08 AM |
| PRA Health Sciences, Inc. (NASDAQ:PRAH) to Post Q3 2017 Earnings of $0.83 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - August 14 at 2:30 AM |
| PRA Health Sciences, Inc. (NASDAQ:PRAH) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - August 14 at 12:26 AM |
| Q4 2017 EPS Estimates for PRA Health Sciences, Inc. Decreased by Jefferies Group (NASDAQ:PRAH)
www.americanbankingnews.com - August 11 at 1:04 PM |
| William Blair Comments on PRA Health Sciences, Inc.'s Q3 2017 Earnings (PRAH)
www.americanbankingnews.com - August 11 at 10:45 AM |
| PRA Health Sciences, Inc. :PRAH-US: Earnings Analysis: Q2, 2017 By the Numbers : August 10, 2017
finance.yahoo.com - August 11 at 7:43 AM |
| Pharmaceutical Research Associates, Inc. -- Moody's affirms PRA Holdings; outlook to stable from positive
finance.yahoo.com - August 11 at 7:43 AM |
| PRA Health Sciences (PRAH) Prices Secondary Stock Offering
finance.yahoo.com - August 11 at 7:43 AM |
| PRA Health Sciences' (PRAH) Buy Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - August 10 at 10:40 PM |
| PRA Health Sciences, Inc. (NASDAQ:PRAH) Stock Rating Reaffirmed by Citigroup Inc.
www.americanbankingnews.com - August 10 at 12:47 PM |
| William Blair Comments on PRA Health Sciences, Inc.'s Q4 2017 Earnings (NASDAQ:PRAH)
www.americanbankingnews.com - August 10 at 10:46 AM |
| PRA Health Sciences, Inc. Announces Pricing of Secondary Offering of 10,000,000 Shares of Common Stock
finance.yahoo.com - August 10 at 7:00 AM |
| PRA Health Sciences, Inc. breached its 50 day moving average in a Bullish Manner : PRAH-US : August 9, 2017
finance.yahoo.com - August 10 at 7:00 AM |
| PRA Health Sciences Gaps Up On Earnings
finance.yahoo.com - August 9 at 6:31 AM |
| Investor Network: PRA Health Sciences, Inc. to Host Earnings Call
finance.yahoo.com - August 9 at 6:31 AM |
| Edited Transcript of PRAH earnings conference call or presentation 8-Aug-17 1:00pm GMT
finance.yahoo.com - August 9 at 6:31 AM |
| PRA Health Sciences, Inc. Announces Secondary Offering of 10,000,000 Shares of Common Stock
finance.yahoo.com - August 9 at 6:31 AM |
| PRA Health Sciences, Inc. (NASDAQ:PRAH) Price Target Raised to $84.00
www.americanbankingnews.com - August 8 at 11:10 AM |
| PRA Health Sciences, Inc. (PRAH) Expected to Announce Quarterly Sales of $447.88 Million
www.americanbankingnews.com - August 8 at 7:44 AM |
| PRA Health Sciences to acquire Symphony Health Solutions, a leading provider ...
www.nasdaq.com - August 8 at 6:20 AM |
| PRA Health Sciences to acquire Symphony Health Solutions, a leading provider ...
www.nasdaq.com - August 8 at 6:20 AM |
 | PRA Health Sciences (PRAH) to acquire Symphony Health Solutions
www.streetinsider.com - August 8 at 6:20 AM |
| PRA Health Sciences (PRAH) to acquire Symphony Health Solutions
www.streetinsider.com - August 8 at 6:20 AM |
| [$$] PRA to Buy Private Equity-Backed Symphony Health Solutions
finance.yahoo.com - August 8 at 6:20 AM |
| [$$] PRA to Buy Private Equity-Backed Symphony Health Solutions
finance.yahoo.com - August 8 at 6:20 AM |
| PRA to buy data and analytics company for $530M+
finance.yahoo.com - August 8 at 6:20 AM |
| PRA to buy data and analytics company for $530M+
finance.yahoo.com - August 8 at 6:20 AM |
PRA Health Sciences (PRAH) Chart for Friday, September, 22, 2017
